Looking Into Myovant Sciences's Return On Invested Capital

Author: Benzinga Insights | October 28, 2022 10:11am

Benzinga Pro data, Myovant Sciences (NYSE:MYOV) reported Q2 sales of $104.82 million. Earnings fell to a loss of $45.62 million, resulting in a 114.79% decrease from last quarter. Myovant Sciences collected $116.49 million in revenue during Q1, but reported earnings showed a $21.24 million loss.

What Is ROIC?

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q2, Myovant Sciences posted an ROIC of 21.81%.

Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

ROIC is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROIC shows Myovant Sciences is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of invested capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Myovant Sciences, the positive return on invested capital ratio of 21.81% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Upcoming Earnings Estimate

Myovant Sciences reported Q2 earnings per share at $-0.47/share, which beat analyst predictions of $-0.48/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: MYOV